Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia

A. T. Maiolo, P. Foa, M. Cortellaro, G. Lambertenghi-Deliliers, A. Colantoni, B. Cesana, G. L. Castoldi, M. Cazzola, M. Giordano, A. Riccardi

Research output: Contribution to journalArticle

Abstract

Thirthy-six patients with refractory anemia with excess of blasts in transformation (RAEBt), or acute myelogenous leukemia (AML) after myelodysplastic syndrome, and twenty-four patients with 'de novo' AML were treated with cytosine arabinoside (Ara-C) in low dosage. The two groups of patients were comparable with respect to age, hemoglobin level, white cell and platelet counts. Ara-C was administered subcutaneously at a dose of 10 mg/m2 every 12 hours for 21 days. Treatments were repeated every 2-3 months depending on marrow cellularity. Overall, 30% complete response and 48% partial response were observed. Neutropenia and thrombocytopenia were frequent complications. Median survival from the start of treatment was 7 months in both groups; at least 25% of patients survived more than 12 months. Survival appeared to be related to treatment response: patients achieving complete remission survived significantly longer than those who had partial remission.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalHaematologica
Volume72
Issue number1
Publication statusPublished - 1987

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Maiolo, A. T., Foa, P., Cortellaro, M., Lambertenghi-Deliliers, G., Colantoni, A., Cesana, B., Castoldi, G. L., Cazzola, M., Giordano, M., & Riccardi, A. (1987). Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia. Haematologica, 72(1), 61-65.